##  [FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity](/us-en/news/media-releases/fda-approves-supplemental-new-drug-application-novartis-therapy-gilenyatm-include-data-showing-reduction-t1-lesions-ms-marker-disease-activity-0 "FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity") 

  Aug 01, 2011